What is FDMT's P/E ratio?

4D Molecular Therapeutics Inc (FDMT) currently trades at a P/E ratio of 27.19.

4D Molecular Therapeutics Inc reports a Return on Equity (ROE) of -35.61%.

What is FDMT's dividend yield?

4D Molecular Therapeutics Inc offers a dividend yield of 0.00%.

What is FDMT's Quality Score?

Our AI rates FDMT's overall financial quality at 23 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy FDMT?

Our AI Timing Score for FDMT is 55 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does FDMT belong to?

4D Molecular Therapeutics Inc is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange

4D Molecular Therapeutics Inc (FDMT) Stock Price

Stock Check Daily update data at 8:30 AM
(Price: 2026-08-04 | FS: 2026-03-31)

FDMT AI Analysis Summary

Our AI summary for FDMT: 4D Molecular Therapeutics Inc (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 27.19, ROE of -35.61%, a dividend yield of 0.00%. Its financial Quality Score stands at 23/100 — fundamentals below the market average. The AI Timing Score is 55/100 — technical signals are mixed; watch for a clearer trend. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

FDMT

4D Molecular Therapeutics Inc

US:NASDAQ STOCK Healthcare >> Biotechnology News 90

USD 10.26

0.17 (1.68%) Day Change

Watchlist Portfolio Compare Chart

27.19

P/E

0.01

D/E

-35.6%

ROE

-31.4%

ROA

0.00%

Div Yield

-3.94

PEG

4D MOLECULAR THERAPEUTICS INC
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 10.26 Price 0.17 (1.68%) Day Change	NEWS SCORE: 90

FDMT, the overall quality is not good ( Quality = 23) and the timing to buy is ...(Sign In to See)...

Loading chart...

23 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
ROE is decreasing significantly
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Historical net profit margin is relatively low.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...

Quality Factors

42%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	90
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	10.26
PBV / Sector	1.17 / 44,022.72 GREAT
Earning Per Share	-3.13

PE / Sector	27.19 / 19.17
PEG or PE/Growth / Sector	-3.94 / 1.24
Average 1M Daily Value	6.92 M
Average 1W Daily Value	5.15 M GREAT

Timing Factors

28%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

47%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

56%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	-182.34 / 98.24
NPM Average (%) / Sector	-87,768.41 / -1,697.63
NPM Change Average (%) / Sector	22,269.31 / 5,097.97 GREAT
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-31.37 / 185,260.96
ROA Average (%) / Sector	-30.61 / 36,684.70
ROA Change Average (%) / Sector	-3.34 / 422,221.66
ROE (%) / Sector	-35.61 / 243,762.23
ROE Average (%) / Sector	-34.25 / 48,758.47
ROE Change Average (%) / Sector	-3.10 / 424,968.10
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -0.49

Registration Details

Analyze Date	2026-08-05 08:00:11
Symbol	FDMT
Name	4D MOLECULAR THERAPEUTICS INC
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	52.28 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	527.47 / 9,586.08

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 5858 Horton Street, EmeryVille, CA, United States, 94608

Phone: 510 505 2680

Website: https://www.4dmoleculartherapeutics.com

Employees: 196

Sector: Healthcare >> Biotechnology

Description: 4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. It is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in preclinical stage for treating geographic atrophy; and 4D-725, which is in preclinical stage for the treatment of alpha-1 anti-trypsin deficiency lung disease. 4D Molecular Therapeutics, Inc. has collaboration and licensing agreements with Otsuka Pharmaceutical Co., Ltd. The company was founded in 2013 and is headquartered in EmeryVille, California.